{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:46:03Z","timestamp":1794815163812,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This retrospective observational study (NEUF) included adult patients with B-cell acute lymphoblastic leukemia (B-cell ALL) who had received blinatumomab for the treatment of minimal residual disease-positive (MRD+) or relapsed\/refractory (R\/R) B-cell ALL via an expanded access program (EAP). Patients were eligible if blinatumomab was initiated via the EAP between January 2014 and June 2017. Patients were followed from blinatumomab initiation until death, entry into a clinical trial, the end of follow-up, or the end of the study period (December 31, 2017), whichever occurred first. Of the 249 adult patients included, 109 were MRD+\u2009(83 Philadelphia chromosome-negative [Ph\u2212] and 26 Philadelphia chromosome-positive [Ph+]) and 140 had a diagnosis of R\/R B-cell ALL (106 Ph\u2212 and 34 Ph+). In the MRD+\u2009group, within the first cycle of blinatumomab treatment, 93% (<jats:italic>n<\/jats:italic>\u2009=\u200949\/53) of Ph\u2212 and 64% (<jats:italic>n<\/jats:italic>\u2009=\u20097\/11) of Ph+ patients with evaluable MRD achieved an MRD response (MRD\u2009&lt;0.01%). Median overall survival (OS) was not reached over a median follow-up time of 18.5 months (Ph\u2212, 18.8 [range: 5.1\u201334.8] months; Ph+, 16.5 [range: 1.8\u201331.6] months). In the R\/R group, within two cycles of blinatumomab, 51% of Ph\u2212 and 41% of Ph+ patients achieved complete hematologic remission (CR\/CRh\/CRi), and 83% of Ph\u2212 and 67% of Ph+ MRD-evaluable patients in CR\/CRh\/CRi achieved an MRD response. Median (95% confidence interval) OS was 12.2 (7.3\u201324.2) months in the R\/R Ph\u2212 subgroup and 16.3 (5.3\u2013not estimated) months in the R\/R Ph+ subgroup. This large, real-world data set of adults with B-cell ALL treated with blinatumomab confirms efficacy outcomes from published studies.<\/jats:p>","DOI":"10.1038\/s41408-022-00766-7","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T08:04:54Z","timestamp":1672819494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-7927","authenticated-orcid":false,"given":"Nicolas","family":"Boissel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Chiaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-6024","authenticated-orcid":false,"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-2894","authenticated-orcid":false,"given":"Renato","family":"Bassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1494-7978","authenticated-orcid":false,"given":"Andrey N.","family":"Sokolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naufil","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Brescianini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Pezzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Kreuzbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-2671","authenticated-orcid":false,"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"766_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-019-0152-y","volume":"8","author":"J Zhao","year":"2019","unstructured":"Zhao J, Song Y, Liu D. Recent advances on blinatumomab for acute lymphoblastic leukemia. Exp Hematol Oncol. 2019;8:28.","journal-title":"Exp Hematol Oncol"},{"key":"766_CR2","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","DOI":"10.1182\/blood-2017-08-798322"},{"key":"766_CR3","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Dombret H, Giebel S, Bruggemann M, Doubek M, Foa R, et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019;24:337\u201348.","DOI":"10.1080\/16078454.2019.1567654"},{"key":"766_CR4","unstructured":"Blinatumomab summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blincyto-epar-product-information_en.pdf. Accessed November 23, 2022."},{"key":"766_CR5","doi-asserted-by":"crossref","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974\u20137.","DOI":"10.1126\/science.1158545"},{"key":"766_CR6","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","volume":"61","author":"N G\u00f6kbuget","year":"2020","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, et al. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61:2665\u201373.","journal-title":"Leuk Lymphoma"},{"key":"766_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57\u201366.","journal-title":"Lancet Oncol"},{"key":"766_CR8","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134\u201340.","journal-title":"J Clin Oncol"},{"key":"766_CR9","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","DOI":"10.1056\/NEJMoa1609783"},{"key":"766_CR10","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","volume":"60","author":"H Dombret","year":"2019","unstructured":"Dombret H, Topp MS, Schuh AC, Wei AH, Durrant S, Bacon CL, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60:2214\u201322.","journal-title":"Leuk Lymphoma"},{"key":"766_CR11","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1002\/cam4.3731","volume":"10","author":"MS Topp","year":"2021","unstructured":"Topp MS, Stein AS, G\u00f6kbuget N, Horst HA, Boissel N, Martinelli G, et al. Blinatumomab as first salvage versus second or later salvage in adults with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: results of a pooled analysis. Cancer Med. 2021;10:2601\u201310.","journal-title":"Cancer Med"},{"key":"766_CR12","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Topp MS, et al. Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795\u2013802.","journal-title":"J Clin Oncol"},{"key":"766_CR13","doi-asserted-by":"crossref","unstructured":"Cabannes-Hamy A, Brissot E, Leguay T, Huguet F, Chevallier P, Hunault M, et al. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. Haematologica. 2022;107:2072\u201380.","DOI":"10.3324\/haematol.2021.280078"},{"key":"766_CR14","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/bloodadvances.2019001381","volume":"4","author":"T Badar","year":"2020","unstructured":"Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, et al. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020;4:2308\u201316.","journal-title":"Blood Adv"},{"key":"766_CR15","doi-asserted-by":"publisher","first-page":"804714","DOI":"10.3389\/fonc.2021.804714","volume":"11","author":"M Bonifacio","year":"2021","unstructured":"Bonifacio M, Papayannidis C, Lussana F, Fracchiolla N, Annunziata M, Sica S, et al. Real-world multicenter experience in tumor debulking prior to blinatumomab administration in adult patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Front Oncol. 2021;11:804714.","journal-title":"Front Oncol"},{"key":"766_CR16","doi-asserted-by":"publisher","first-page":"e29562","DOI":"10.1002\/pbc.29562","volume":"69","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Maschan A, Boissel N, Strocchio L, Alam N, Pezzani I, et al. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: results from the NEUF study. Pediatr Blood Cancer. 2022;69:e29562.","journal-title":"Pediatr Blood Cancer"},{"key":"766_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.84","volume":"6","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. Blinatumomab vs historical standard therapy of adult relapsed\/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016;6:e473.","journal-title":"Blood Cancer J"},{"key":"766_CR18","doi-asserted-by":"crossref","unstructured":"Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008. Leukemia. 2010;24:521\u201335.","DOI":"10.1038\/leu.2009.268"},{"key":"766_CR19","doi-asserted-by":"crossref","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe Against Cancer program. Leukemia. 2003;17:2318\u201357.","DOI":"10.1038\/sj.leu.2403135"},{"key":"766_CR20","doi-asserted-by":"crossref","unstructured":"Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129:347\u201357.","DOI":"10.1182\/blood-2016-07-726307"},{"key":"766_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5002-5","volume":"18","author":"A Pigneux","year":"2018","unstructured":"Pigneux A, Montesinos P, Cong Z, Zhang X, Pownell AK, Wieffer H, et al. Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. BMC Cancer. 2018;18:1100.","journal-title":"BMC Cancer"},{"key":"766_CR22","doi-asserted-by":"crossref","unstructured":"Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189\u201397.","DOI":"10.1182\/blood-2006-10-051912"},{"key":"766_CR23","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Foa","year":"2020","unstructured":"Foa R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"766_CR24","doi-asserted-by":"crossref","unstructured":"Puzzolo MC, Radice G, Peragine N, de Propris MS, Mariglia P, Vignetti M, et al. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. Blood. 2021;138:2290\u20133.","DOI":"10.1182\/blood.2021011822"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00766-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T08:08:43Z","timestamp":1672819723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00766-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00766-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"5 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nicolas Boissel received honoraria from Amgen, Ariad, Jazz, Pfizer, Servier, and Shire. Sabina Chiaretti received honoraria for advisory boards from Amgen Inc., Incyte, Pfizer, and Shire. Cristina Papayannidis received honoraria from Amgen, Novartis, Pfizer, Shire, and Teva Pharmaceuticals for travel, sponsored lectures, and advisory board meetings. Josep-Maria Ribera received research funds and honoraria from, and served on advisory boards for, Amgen, Incyte, Novartis, Pfizer, and Shire. Renato Bassan received honoraria for advisory boards from Amgen Inc., Incyte, Pfizer, and Shire. Andrey N. Sokolov received support from Amgen, Astellas, Novartis, and Pfizer for travel and sponsored lectures. Naufil Alam and Georg Kreuzbauer were employees of Amgen at the time of this work and still hold stocks of Amgen Inc. Alessandra Brescianini and Isabella Pezzani are employees and stockholders of Amgen. Gerhard Zugmaier is employed by Amgen Research (Munich) GmbH, owns stock in Amgen Inc., and holds patents relating to blinatumomab. Robin Fo\u00e0 received honoraria for speaker bureau and advisory boards for Amgen Inc., Incyte, Janssen, Novartis, and Pfizer. Alessandro Rambaldi received support from Amgen, Celgene, Novartis, and Pfizer for travel, sponsored lectures, and advisory board meetings.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}